药物adagrasib有效抑制携带KRASG12C突变的癌症类型 在治疗胃肠道癌症患者中展现出临床活性
发布时间：
2022-02-15
来源：
作者：
阅读数：
胃肠道癌症是一些最常被诊断出的人类癌症，这类癌症往往与患者不良的生存结局有关，而药物adagrasib能特异性地靶向作用KRASG12C基因突变，该基因突变在胃肠道癌症中非常常见，其能抑制机体胃肠道的功能。（推荐阅读：MKN74人胃癌细胞、FU97人胃癌细胞、SNU-16人胃癌细胞、NS-3人胃癌细胞、GTL16人胃癌细胞）
研究者Tanios Bekaii-Saab博士表示，我们对药物adagrasib进行了一系列研究，结果发现，其在治疗携带KRAS G12C突变的胃肠道癌症患者中具有非常良好的临床活性，包括胰腺癌、胆道癌和其它上消化道癌症等，近日，Tanios Bekaii-Saab博士在召开的美国临床肿瘤学会泌尿生殖系统癌症研讨会上介绍了作为KRYSTAL-1临床试验（NCT03785249）的一部分的研究结果。
研究者Bekaii-Saab表示，携带KRAS基因突变的癌症患者的预后往往较差，而科学家们也在一直研究尝试靶向作用KRAS G12C，但均以失败而告终；KRAS G12C在这组癌症中所有的KRAS突变中占比不到5%的比例。相关研究数据最近在研讨会上公布，研究者发现，药物adagrasib不仅能有效抑制携带KRASG12C突变的癌症类型，还在治疗胃肠道癌症患者中展现出了一定的临床活性。（推荐阅读：WiDr人大肠癌细胞、C26小鼠结肠癌、H508人结肠癌细胞）
在2期队列研究中所有接受这种新型疗法的胃肠道癌症患者的疾病都得到了控制，近一半的患者表现出了明显且持久的肿瘤萎缩效应和证据。研究者表示，在治疗一组结果表现较差的疾病上，这些研究结果或许令人印象非常深刻，而研究人员对这些研究发现感到非常惊喜，因为他们之前使用的另一类相似药物的经验在这一特殊的患者群体中所得到的结果往往令人失望。
目前研究人员正在对adagrasib药物进行研究，如果这些较好的治疗效果的趋势继续下去的话，这种药物最终或有望作为一种新型疗法来帮助治疗胰腺癌、胆道癌以及其它胃肠道癌症等。（推荐阅读：KP-1N人胰腺癌细胞、HS766T、COLO-587、MPANC-96人胰腺癌细胞、胰腺癌原位模型）
原始出处：
Researchers identify promising drug to treat gastrointestinal cancers
by Joe Dangor, Mayo Clinic
Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Tanios Bekaii-Saab, M.D., an investigator from Mayo Clinic Cancer Center, has conducted research on adagrasib that has demonstrated promising clinical activity in patients with gastrointestinal cancers that harbor KRAS G12C mutations, including pancreatic cancer, biliary tract cancer and other upper gastrointestinal cancers. Dr. Bekaii-Saab recently presented the results of this research as part of the KRYSTAL-1 clinical trial (NCT03785249) at the American Society of Clinic Oncology's Genitourinary Cancers Symposium.
"The prognosis for patients whose cancer harbors a KRAS gene mutation is particularly poor, and researchers' attempts to target KRAS G12C, which represents less than 5% of all KRAS mutations in this group of cancers, have failed until only recently," says Dr. Bekaii-Saab.
"Our data recently presented at ASCO GI (the symposium) showed that adagrasib not only inhibits cancers with a KRASG12C mutation effectively, but also showed promising clinical activity in patients with gastrointestinal cancers."
Dr. Bekaii-Saab says the gastrointestinal cancers for all patients treated in this phase 2 cohort were controlled, with close to half showing evidence of significant and durable tumor shrinkage.
"These results were very impressive in treating a group of diseases that tend to have a particularly poor outcome," says Dr. Bekaii-Saab. "We were pleasantly surprised by these findings, given that our previous experience with another similar agent was disappointing in this particular group of patients."
He says research with adagrasib is ongoing. If these trends continue, the drug may eventually prove to be a new option for patients with pancreatic, biliary tract and other gastrointestinal cancers.......
相关新闻
24小时热线 18802035152(微信同号)/QQ:3691125803
广州黄埔区南云五路11号光正科技园A栋2楼238
24小时客服
微信公众号